Israel -
Englisch -
Ministry of Health
lynparza 50 mg
astra zeneca (israel) ltd - olaparib - hard capsule - olaparib 50 mg - olaparib - lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed brca-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, (including fallopian tube, or primary peritoneal) cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
Israel -
Englisch -
Ministry of Health
sovaldi
gilead sciences israel ltd - sofosbuvir - film coated tablets - sofosbuvir 400 mg - sofosbuvir - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults.for hepatitis c virus (hcv) genotype specific activity, see physician leaflet .
Israel -
Englisch -
Ministry of Health
sovaldi
gilead sciences israel ltd - sofosbuvir - film coated tablets - sofosbuvir 400 mg - sofosbuvir - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults.for hepatitis c virus (hcv) genotype specific activity, see physician leaflet .
Israel -
Englisch -
Ministry of Health
sovaldi
gilead sciences israel ltd - sofosbuvir - film coated tablets - sofosbuvir 400 mg - sofosbuvir - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults.for hepatitis c virus (hcv) genotype specific activity, see physician leaflet .
Israel -
Englisch -
Ministry of Health
rezolsta
j-c health care ltd - cobicistate; darunavir as ethanolate - film coated tablets - cobicistate 150 mg; darunavir as ethanolate 800 mg - darunavir - rezolsta is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv 1) infection in treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions (v11i, v32i, l33f, i47v, i50v, i54l, i54m, t74p, l76v, i84v, l89v).שינוי משטר מינון 2/4/2019pregnancy and postpartumtreatment with rezolsta during pregnancy results in low darunavir exposure (see sections 4.4 and 5.2). therefore, therapy with rezolsta should not be initiated during pregnancy, and women who become pregnant during therapy with rezolsta should be switched to an alternative regimen, see section 4.4 and 4.6. darunavir/ritonavir may be considered as an alternative.
Europäische Union -
Englisch -
EMA (European Medicines Agency)
vocabria
viiv healthcare b.v. - cabotegavir sodium, cabotegravir - hiv infections - antivirals for systemic use - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna
Europäische Union -
Englisch -
EMA (European Medicines Agency)
rekambys
janssen-cilag international nv - rilpivirine - hiv infections - antivirals for systemic use - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.
Europäische Union -
Englisch -
EMA (European Medicines Agency)
apretude
viiv healthcare b.v. - cabotegravir - hiv infections - antivirals for systemic use - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4.2, 4.4 and 5.1).
